Please Wait
Applying Filters...
menu
    • menu
    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

    Virtual Booth

    Contact Supplier

    Inke S.A: APIs manufacturing plant.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-04-21

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-04-14

    Virtual Booth

    Contact Supplier

    Menu

    Zidesamtinib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Nuvalent Shares Updated Data On ALK And ROS1 Inhibitors
    Nuvalent Shares Updated Data On ALK And ROS1 Inhibitors

    09 Sep 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/updated-data-for-nuvalents-alk-selective-inhibitor-nvl-655-and-ros1-selective-inhibitor-zidesamtinib-continue-to-support-potential-best-in-class-profiles-302241297.html

    PR NEWSWIRE
    09 Sep 2024
    Share Share
    Nuvalent To Present ROS1 And ALK Inhibitor Data At ESMO 2024
    Nuvalent To Present ROS1 And ALK Inhibitor Data At ESMO 2024

    16 Jul 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/nuvalent-to-present-updated-data-for-ros1-selective-inhibitor-zidesamtinib-and-alk-selective-inhibitor-nvl-655-at-the-esmo-congress-2024-302197499.html

    PR NEWSWIRE
    16 Jul 2024
    Share Share
    Nuvalent Presents New Preclinical Data of Zidesamtinib at AACR
    Nuvalent Presents New Preclinical Data of Zidesamtinib at AACR

    08 Apr 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/nuvalent-presents-new-preclinical-data-supporting-profiles-of-her2-selective-inhibitor-nvl-330-and-ros1-selective-inhibitor-zidesamtinib-at-aacr-annual-meeting-2024-302110869.html

    PR NEWSWIRE
    08 Apr 2024
    Share Share
    Nuvalent to Present New Preclinical Data on NVL-330, and zidesamtinib
    Nuvalent to Present New Preclinical Data on NVL-330, and zidesamtinib

    05 Mar 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/nuvalent-to-present-new-preclinical-data-on-her2-selective-inhibitor-nvl-330-and-ros1-selective-inhibitor-zidesamtinib-at-aacr-annual-meeting-2024-302080625.html

    PR NEWSWIRE
    05 Mar 2024
    Share Share